Chicken wings, appliances, software, an airline and another biotech company all will debut in the suddenly humming IPO market this week.

Regional carrier

Pinnacle Airlines

(PNCL:Nasdaq), a spinoff of

Northwest Airlines

( NWAC), is scheduled to sell 19.4 million shares at between $15 to $17.

The Memphis, Tenn.-based operator is expected to price on Thursday through underwriters led by

Bear Stearns

and Banc of America Securities.

In a calendar dominated by bricks-and-mortar companies, also watch for

Nexstar Broadcasting

(WLL:NYSE), a group of TV stations run out of Irving, Texas, which is selling 10 million shares within a $14 to $16 range.

Also in that range is

Whiting Petroleum

, an oil and gas explorer based in Denver being spun off by

Alliant Energy

(LNT) - Get Report

, which is selling 15 million shares, underwritten by A.G. Edwards and Merrill Lynch; and

Buffalo Wild Wings

, a Minneapolis-based restaurant chain specializing in chicken wings, with about 2.7 million shares being sold through SG Cowen and RBC Capital Markets. Buffalo Wild is expected to be priced Thursday.

Three IPOs are all about the same size with $12-$14 price ranges: Cambridge, Mass.-based biotech

TolerRx

(TLRX:Nasdaq), selling 4.7 million shares (S.G. Cowen, J.P. Morgan); San Jose, Calif.-based

Callidux Software

(CALD:Nasdaq), selling 5 million shares (Citigroup); and

Coons

(CONN:Nasdaq), a consumer electronics and appliance retailer based in Beaumont, Texas, selling 4.15 shares (BancBoston Robertson Stephens, Robinson-Humphrey). All are expected to be priced on Wednesday.

Last week, three strong debuts from three very different companies hit the market. Semiconductor company

Tessera

(TSRA)

on Thursday led the way with a 42% gain.

LECG

(XPRT)

, which provides expert witnesses and analysis for legal, legislative and regulatory issues, jumped more than 20% on Friday while equipment-lessor

Marlin Business Services

(MRLN) - Get Report

rose 15% on its first day of trading Wednesday.

In recent weeks, there has been a rash of biotech IPOs that have generally performed poorly and are down since their October debuts.